Search Results
Jul 28, 2025, 17:31 ET Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
initiatives are supporting the growth of innovative startups working on novel alpha-synuclein-targeting approaches, such as antisense oligonucleotides and gene therapy-based strategies. Looking ahead, the alpha-synuclein inhibitors market is poised for steady growth. The next decade is expected to witness
More news about: DelveInsight Business Research, LLP
Jul 28, 2025, 17:00 ET RCKT INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
11, 2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided
More news about: Robbins Geller Rudman & Dowd LLP
Jul 28, 2025, 16:19 ET PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
About PhenylketonuriaPhenylketonuria (PKU) is a rare, inherited metabolic disease, which affects the brain. It is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe). If left untreated or poorly managed, Phe—an essential amino acid found in all
More news about: PTC Therapeutics, Inc.
Jul 28, 2025, 15:03 ET Biologic Therapeutics Market to Hit $794.5 Billion by 2029
"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON,
More news about: BCC Research LLC
Jul 28, 2025, 09:19 ET Chungnam National University Researchers Reveal How Vitamin D is Shown to Reduce Liver Damage by Boosting TXNIP Activity in Cholangiocytes
A new study uncovers how vitamin D activates the TXNIP gene in ductular cells to reduce inflammation and fibrosis in chronic liver disease DAEJEON, South Korea, July
More news about: Chungnam National University
Jul 28, 2025, 09:00 ET Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
(autosomal dominant), progressive neuromuscular disease that shortens life expectancy and requires life-long care caused by a triplet-repeat in the DMPK gene, resulting in a toxic gain of function mRNA. The disease is highly variable with respect to severity, presentation and age of onset, however, all forms
More news about: Avidity Biosciences, Inc.
Jul 28, 2025, 08:45 ET The Gross Law Firm Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Gross Law Firm
Jul 28, 2025, 08:05 ET BioLife Solutions Makes Strategic Investment in Pluristyx
BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible
More news about: BioLife Solutions, Inc.
Jul 28, 2025, 08:00 ET Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting
biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative diseases, announced that its multi-characteristic opsin (MCO) gene therapy platform will be featured in a presentation by Dr. David
More news about: Nanoscope Therapeutics
Jul 28, 2025, 07:59 ET South Rampart Pharma Announces New Study in Neurobiology of Pain Demonstrating How SRP-001 Delivers Central, Non-Toxic Pain Relief
suppresses AP-1 family and TFEB transcription factor activities, indicating potential anti-inflammatory and analgesic effects independent of changes in gene expression. SRP-001 effectively restores Neurexin-Neuroligin synaptic signaling disrupted by inflammatory pain, underscoring its potential
More news about: South Rampart Pharma
Jul 27, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 25, 2025, 21:05 ET UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
shown to accelerate multi-organ deterioration. "The Klotho gene is what we call a master gene," stated Shalom Hirschman, M.D., world-renowned physician and senior consultant to the Company. "The Klotho gene has pleotropic actions modulating many critical cellular pathways
More news about: Klotho Neurosciences, Inc.
Jul 25, 2025, 15:40 ET AstraZeneca - Anvisa aprova terapia-alvo para câncer de pulmão não elegível a cirurgia com potencial de reduzir em 84% o risco de progressão ou morte
https://vencerocancer.org.br/tipos-de-cancer/cancer-de-pulmao-o-que-e/. Acesso em 16 de outubro de 2024. [6] Lopes, GL; et al. Identificação de mutações ativadoras no gene EGFR: implicações no prognóstico e no tratamento do carcinoma pulmonar de células não pequenas. J Bras Pneumol. 2015; 41(4):365-375. [7] National
More news about: AstraZeneca
Jul 25, 2025, 08:49 ET Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's
More news about: Eli Lilly and Company
Jul 25, 2025, 08:45 ET Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Jul 25, 2025, 06:27 ET Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
do not usually cause any symptoms, but serious and life-threatening symptoms can occur. ARIA can be fatal. Carriers of one or two copies of the ApoE4 gene may be at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers.
More news about: Eli Lilly and Company
Jul 25, 2025, 06:22 ET Weekly Recap: 12 Health Press Releases You Need to See
Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets "KLTO hopes to work with AAVnerGene for manufacturing several of our product candidates composed of a tissue-specific promoter driving our Klotho gene to produce the Klotho protein and elevated concentrations
More news about: PR Newswire
Jul 24, 2025, 17:00 ET Ecovyst to Host Second Quarter 2025 Earnings Conference Call and Webcast on Thursday, August 7, 2025 at 11:00 a.m. ET
https://www.ecovyst.com. Investor Contact: Gene Shiels(484) 617 [email protected]
More news about: Ecovyst Inc.
Jul 24, 2025, 16:05 ET BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday,
More news about: BioLife Solutions, Inc.
Jul 24, 2025, 13:30 ET Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
accelerate multi-organ deterioration. "The Klotho gene is what we call a "master gene" stated Shalom Hirschman, M.D., world renowned physician and senior consultant to KLTO. Dr. Hirschman goes on to say "the Klotho gene has pleotropic actions modulating many critical cellular
More news about: Klotho Neurosciences, Inc.
Jul 24, 2025, 09:00 ET Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations
Foundation for Parkinson's Research (MJFF) to advance its GCase-targeting small molecules for GBA1 Parkinson's disease. Mutations of the GBA1 gene, encoding the enzyme GCase, represent the single largest genetic risk factor for Parkinson's Disease. Congruence has leveraged its powerful computational
More news about: Congruence Therapeutics
Jul 24, 2025, 08:45 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 24, 2025, 08:00 ET Lilly and Verve announce expiration of Verve tender offer
single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the
More news about: Eli Lilly and Company
Jul 24, 2025, 07:00 ET Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated